Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC ; day:19 ; month:9 ; year:2020 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (19.9.2020), 1-11
- Urheber
-
Kramer, Vasko
Fernández, René
Lehnert, Wencke
Jiménez-Franco, Luis David
Soza-Ried, Cristian
Eppard, Elisabeth
Ceballos, Matias
Meckel, Marian
Benešová, Martina
Umbricht, Christoph A.
Kluge, Andreas
Schibli, Roger
Zhernosekov, Konstantin
Amaral, Horacio
Müller, Cristina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-020-05022-3
- URN
-
urn:nbn:de:101:1-2020110815534132752095
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kramer, Vasko
- Fernández, René
- Lehnert, Wencke
- Jiménez-Franco, Luis David
- Soza-Ried, Cristian
- Eppard, Elisabeth
- Ceballos, Matias
- Meckel, Marian
- Benešová, Martina
- Umbricht, Christoph A.
- Kluge, Andreas
- Schibli, Roger
- Zhernosekov, Konstantin
- Amaral, Horacio
- Müller, Cristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies](/assets/placeholder/searchResultMediaUnknown.png)
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Towards personalized internal radionuclide therapies with 90Y SIRT and 177Lu-PSMA: an investigation of 3D image based dosimetry
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
Towards personalized internal radionuclide therapies with 90Y SIRT and 177Lu-PSMA: an investigation of 3D image based dosimetry
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]